Literature DB >> 25550864

HBV serum and renal biopsy markers are associated with the clinicopathological characteristics of HBV-associated nephropathy.

Zhao Tan1, Jing Fang1, Jian-Hua Lu1, Wen-Ge Li1.   

Abstract

BACKGROUND: Accumulated evidence has shown that hepatitis B virus infection is associated with numerous types of nephropathy but it remains to clarify the different role of HBV markers, either in serum or deposit in kidney, in the pathogenesis of HBV-associated nephropathy. In this study, we investigated the relationship between HBV markers and HBV-associated nephropathy by using multi-linear regression in Chinese patients with HBV-associated membranous nephropathy (MN).
METHODS: A total of 196 cases of HBV-associated MN, which were diagnosed based on renal biopsy, were collected during the period of January 2000 to December 2009 from our hospital. Serum and renal biopsy HBV markers included HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBC. HBV-associated nephropathy was characterized by a panel of clinical manifestations and pathological parameters, which included proteinuria, hematuria, serum creatinine, hypertension, and renal damage in glomeruli, tubules, interstitium, and blood vessels. Multilinear regression was used to analyze the relationship between the HBV markers in serum and renal biopsy and the clinicopathological characteristics of HBV-associated nephropathy.
RESULTS: After analysis of the clinical and pathological data in 196 cases of HBV-associated membranous nephropathy, this study revealed that glomerular lesion was marginally associated with serum HBsAg (P = 0.0528), Anti-HBs (P = 0.0978), but significantly associated with the presence of IgA (P = 0.0242), IgG (P < 0.0001) and C3 (P = 0.0064) in renal biopsy. There was no significant association between glomerular lesion and HBV markers in kidney. The presence of crescent and renal tube impairment was not related to HBV markers. The renal fibrosis was significantly related to gender (P = 0.023), age (P = 0.0211), HBsAg (P = 0.0001) and HBcAg (P = 0.0083) and C3 (P = 0.0299) in renal biopsy. Notably, the renal blood vessel impairment was significantly related to systolic Blood Pressure (SBP) (P < 0.0001), diastolic blood pressure (DBP) (P = 0.0002), serum HBsAg (P = 0.0428), serum HBeAg (P = 0.0766), FRA (P = 0.0002), and HBsAg (P = 0.0241) and HBcAg (P = 0.0599) in renal tissues. Also, the renal interstitial infiltration was related to patient age (P = 0.015, SBP (P < 0.0001), DBP (P = 0.0001), C3 (P = 0.0028), FRA (P = 0.0165), HBsAg (P = 0.0016) and HBcAg (P = 0.0203) in kidney biopsy. These results suggest that the major pathological changes in kidneys in HBV patients are related to one or more HBV markers, such as HBsAg, HBeAg, or anti-HBs antibody. Besides, most of the pathological changes in kidneys are related to C3 and FRA in kidney tissues. The clinical markers of nephropathy, such as proteinuria, hematuria and creatine serum levels, were also evaluated for their relationship with HBV markers in serum and kidney tissues. We found proteinuria was marginally related to HBV DNA (P = 0.0537), significantly related to IgA (0.0223). Hematouria was significantly related to IgA (P = 0.0434), IgG (P < 0.0001), and C1q (P = 0.0282). The serum creatine level was related to patient gender (P = 0.0077), SBP (P < 0.0001), DBP (0.0049), IgG (P-0.0006), and C3 (P = 0.0113). These clinical manifestations were not related to HBV markers in either serum or kidney. These results indicate that some of clinical manifestations of nephropathy are related to HBV markers, but the relationship is limited.

Entities:  

Keywords:  Hepatitis B virus; nephropathy; serum markers

Mesh:

Substances:

Year:  2014        PMID: 25550864      PMCID: PMC4270632     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

Review 1.  The enigmatic X gene of hepatitis B virus.

Authors:  Michael J Bouchard; Robert J Schneider
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Hepatitis B virus infection: implications in chronic kidney disease, dialysis and transplantation.

Authors:  O E Ayodele; B L Salako; S Kadiri; A Arije; C O Alebiosu
Journal:  Afr J Med Med Sci       Date:  2006-06

3.  HBx protein induces expression of MIG and increases migration of leukocytes through activation of NF-kappaB.

Authors:  Li-Min Xia; Wen-Jie Huang; Jian-Guo Wu; Yong-Bo Yang; Qiong Zhang; Zhen-Zhen Zhou; Hui-Fen Zhu; Pin Lei; Guan-Xin Shen; De-An Tian
Journal:  Virology       Date:  2009-01-20       Impact factor: 3.616

Review 4.  Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations.

Authors:  R J Johnson; W G Couser
Journal:  Kidney Int       Date:  1990-02       Impact factor: 10.612

5.  Existence and significance of hepatitis B virus DNA in kidneys of IgA nephropathy.

Authors:  Nian-Song Wang; Zhao-Long Wu; Yue-E Zhang; Lu-Tan Liao
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

6.  HBx protein of hepatitis B virus activates Jak1-STAT signaling.

Authors:  Y H Lee; Y Yun
Journal:  J Biol Chem       Date:  1998-09-25       Impact factor: 5.157

7.  [Detection and analysis of HBV antigen protein in kidney tissue and HBV DNA in serum and kidney tissue of patients with HBsAg+ IgA nephropathy.].

Authors:  L Zhang; X M Jin; Y He; J M Chi; X Ban; Q Huang
Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi       Date:  2006-09

8.  Role of hepatitis B virus infection in pathogenesis of IgA nephropathy.

Authors:  Nian-Song Wang; Zhao-Long Wu; Yue-E Zhang; Mu-Yi Guo; Lv-Tan Liao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  Hepatitis B virus-associated nephropathy in black South African children.

Authors:  R Bhimma; H M Coovadia; M Adhikari
Journal:  Pediatr Nephrol       Date:  1998-08       Impact factor: 3.714

Review 10.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.